ARQT Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. (ARQT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 43% planned / 57% discretionary
Largest single sale: $677.1K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Matsuda Masaru | See Remarks | Sell 10b5-1 | 9,989 | $25.03 | $250.0K | 116,182 −7.9% of holding | |
| Curran Terrie 2 fills | Director | Sell | 38,200 | $25.03 | $956.1K | 23,526 −61.9% of holding | |
| Curran Terrie | Director | Sell | 1,072 | $26.04 | $27.9K | 23,526 −4.4% of holding | |
| Burnett Patrick | See Remarks | Sell | 1,697 | $27.00 | $45.8K | 117,592 −1.4% of holding | |
| Welgus Howard G. | Director | Sell 10b5-1 | 4,730 | $26.18 | $123.8K | 36,475 −11.5% of holding | |
| Burnett Patrick | See Remarks | Sell | 6,700 | $26.08 | $174.8K | 119,289 −5.3% of holding | |
| Burnett Patrick | See Remarks | Sell | 8,300 | $26.52 | $220.1K | 119,289 −6.5% of holding | |
| Watanabe Todd | See Remarks | Sell | 4,375 | $26.12 | $114.3K | 717,203 −0.6% of holding | |
| Matsuda Masaru | See Remarks | Sell | 1,230 | $26.12 | $32.1K | 126,171 −1% of holding | |
| Burnett Patrick | See Remarks | Sell | 955 | $26.12 | $24.9K | 119,289 −0.8% of holding | |
| Welgus Howard G. | Director | Sell 10b5-1 | 4,730 | $26.91 | $127.3K | 37,109 −11.3% of holding | |
| Welgus Howard G. | Director | Sell 10b5-1 | 635 | $25.67 | $16.3K | 37,743 −1.7% of holding | |
| LIN SUE-JEAN | Director | Sell 10b5-1 | 4,946 | $24.38 | $120.6K | 27,567 −15.2% of holding | |
| Welgus Howard G. | Director | Sell 10b5-1 | 4,096 | $24.41 | $100.0K | 38,378 −9.6% of holding | |
| Vairavan Latha | SVP Chief Financial Officer | Sell | 435 | $21.05 | $9.2K | 85,978 −0.5% of holding | |
| Burnett Patrick | See Remarks | Sell | 222 | $21.05 | $4.7K | 120,244 −0.2% of holding | |
| Matsuda Masaru | See Remarks | Sell 10b5-1 | 7,372 | $23.27 | $171.5K | 127,573 −5.5% of holding | |
| Watanabe Todd | See Remarks | Sell | 3,172 | $23.61 | $74.9K | 720,755 −0.4% of holding | |
| Vairavan Latha | SVP Chief Financial Officer | Sell | 1,341 | $23.61 | $31.7K | 86,413 −1.5% of holding | |
| Matsuda Masaru | See Remarks | Sell | 884 | $23.61 | $20.9K | 126,689 −0.7% of holding | |
| Burnett Patrick | See Remarks | Sell | 684 | $23.61 | $16.1K | 120,466 −0.6% of holding | |
| Welgus Howard G. | Director | Sell 10b5-1 | 7,144 | $22.99 | $164.2K | 32,600 −18% of holding | |
| Welgus Howard G. | Director | Sell 10b5-1 | 10,000 | $23.88 | $238.8K | 39,744 −20.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.